Posts by: Marta Figueiredo

Marta Figueiredo

Marta Figueiredo holds a BSc in Biology and a MSc in Evolutionary and Developmental Biology from the University of Lisbon, Portugal. She is currently finishing her PhD in Biomedical Sciences at the University of Lisbon, where she focused her research on the role of several signalling pathways in thymus and parathyroid glands embryonic development.

January 8, 2021January 8, 2021

RHB-204, Oral Treatment for MAC Lung Infections, Put on FDA Fast Track

News

The U.S. Food and Drug Administration (FDA) has given fast track designation to RedHill Biopharma’s RHB-204 as a potential first-line and stand-alone, oral treatment for lung infections caused by ... Read more

December 7, 2020December 7, 2020

Study Recommends Longer Rest Interval Between 6-min Walk Tests for Non-CF Bronchiectasis Patients

News

Two consecutive six-minute walk tests (6MWT) — which measure the distance a patient can walk in that time to assess their exercise capacity — with the recommended rest interval ... Read more

November 26, 2020November 26, 2020

Survey Finds COVID-19 Disrupted Care, Well-Being of Rare Disease Patients in Europe

News, syndicated

The first wave of COVID-19 in Europe severely disrupted access to care and raised stress and anxiety in people with rare diseases, negatively affecting their health and well-being, according to ... Read more

November 23, 2020November 23, 2020

RedHill Launches Trial to Test RHB-204 for Bronchiectasis Plus MAC Lung Infections

News

RedHill Biopharma has launched a Phase 3 clinical trial to evaluate the safety and effectiveness of its investigational oral therapy RHB-204 in adults with bronchiectasis who have lung infections ... Read more

November 2, 2020November 2, 2020

South Korean Tuberculosis Control Program May Have Contributed to Lower Bronchiectasis Rates

News

The number of new cases of bronchiectasis in South Korea gradually decreased from 2005 to 2013, but remained higher than in Western countries, a study shows. Notably, among bronchiectasis’ ... Read more

October 30, 2020October 30, 2020

Arikayce Approved in Europe for MAC Lung Infections in Non-CF Adults

News

The European Commission has approved Arikayce — liposomal amikacin for inhalation — as the first treatment for lung infections caused by Mycobacterium avium complex (MAC), a type of non-tuberculous ... Read more

October 26, 2020October 26, 2020

Bronchiectasis Increases Mortality Risk in People With Steroid-dependent Severe Asthma, Study Finds

News

Bronchiectasis significantly increases the risk of death and hospitalization in people with steroid-dependent severe asthma, according to a study in South Korea. Also, mortality in patients with bronchiectasis was ... Read more

June 15, 2020June 15, 2020

Brensocatib Named FDA Breakthrough Therapy for Non-CF Bronchiectasis

News

Insmed’s brensocatib has been granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA) for the treatment of adults with non-cystic fibrosis bronchiectasis. The designation is given to ... Read more

June 1, 2020June 1, 2020

Most Bronchiectasis Patients in Europe Not Tested for NTM Infection as Recommended, Survey Suggests

News

Many bronchiectasis patients in Europe are not being tested for nontuberculous mycobacteria (NTM) infection before starting macrolide antibiotic treatment, as recommended by current guidelines, according to a small survey of ... Read more

September 27, 2018

Chronic P. Aeruginosa Infection Greatly Raises Risk of Flares in Non-CF Bronchiectasis, Study Shows

News

People with non-cystic fibrosis (CF) bronchiectasis are at a significantly greater risk of exacerbations if they have chronic infections caused by Pseudomonas aeruginosa, a common bacteria that produces specific virulence factors, according to researchers ... Read more